PMID- 11300484
OWN - NLM
STAT- MEDLINE
DCOM- 20010823
LR  - 20061115
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 7
IP  - 3 Suppl
DP  - 2001 Mar
TI  - Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, 
      induce a protective tumor-specific response.
PG  - 865s-870s
AB  - Dendritic cells (DCs) are considered the most potent antigen-presenting cells and 
      probably the only ones able to prime naive T cells. Indeed, DCs are distributed 
      in tissues that interface the external environment, where they act as sentinels 
      for incoming bacteria, viruses, and fungi. We have previously analyzed the 
      capacity of DCs to interact with bacteria, and we have shown that bacteria can 
      act as "Trojan horses," delivering heterologous proteins to DCs in a processed 
      form that allows extremely efficient loading of both MHC class I and class II 
      molecules. In this study, we have optimized the usage of recombinant bacteria as 
      an antigen delivery system for DCs, with the aim to develop a new DC vaccination 
      strategy in antitumor immunity. We have focused on a low immunogenic antigen, the 
      tyrosinase-related protein-2 (Trp-2), a self-antigen expressed in mouse and human 
      melanoma for which induction of antitumor immunity has proven to be very 
      ineffective. We have given mice injections of either Trp-2/recombinant 
      bacteria-loaded DCs or with bacteria alone engineered to express the Trp-2 
      melanoma antigen. We have shown that only DCs loaded with recombinant bacteria, 
      but not with wild-type bacteria, were able to induce Trp-2-specific CTLs and 
      immunity against the B16 tumor. Immunity was obtained in experiments of tumor 
      vaccination as well as in experiments of tumor therapy. When therapy with 
      bacteria-loaded DCs was performed in B16 tumor-bearing mice, 60% of the treated 
      mice were tumor free 2 months after the initial tumor growth.
FAU - Rescigno, M
AU  - Rescigno M
AD  - Department of Biotechnology and Bioscience, University of Milano-Bicocca, Italy.
FAU - Valzasina, B
AU  - Valzasina B
FAU - Bonasio, R
AU  - Bonasio R
FAU - Urbano, M
AU  - Urbano M
FAU - Ricciardi-Castagnoli, P
AU  - Ricciardi-Castagnoli P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, Neoplasm)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.3.12 (dopachrome isomerase)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*metabolism
MH  - Dendritic Cells/*metabolism
MH  - Humans
MH  - Intramolecular Oxidoreductases/*metabolism
MH  - Melanoma, Experimental/metabolism/prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Phenotype
MH  - Salmonella typhimurium/metabolism
MH  - Spleen/cytology/metabolism
MH  - T-Lymphocytes, Cytotoxic/metabolism
MH  - Time Factors
EDAT- 2001/04/13 10:00
MHDA- 2001/08/24 10:01
CRDT- 2001/04/13 10:00
PHST- 2001/04/13 10:00 [pubmed]
PHST- 2001/08/24 10:01 [medline]
PHST- 2001/04/13 10:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2001 Mar;7(3 Suppl):865s-870s.